4-hydroxy-3-methylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydroxy-3-methylbenzamide
• 英文别名: 3-methyl-4-hydroxybenzamide
• 化学式: C₈H₉NO₂
• 分子量: 151.165
• InChiKey: DRJMQBVABWEWOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3-methylbenzamide 在 吡啶 、 三氟乙酸酐 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以81%的产率得到3-甲基-4-羟基-苯甲腈
  参考文献：
  名称：

  3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus

  摘要：

  The human rhinovirus (hRV) is the causative agent of the common cold that often aggravates respiratory complications in patients with asthma or chronic obstructive pulmonary disease. The high rate of mutations and variety of serotypes are limiting the development of anti-hRV drugs, which emphasizes the need for the discovery of novel lead compounds. Previously, we identified antiviral compound 1 that we used here as the starting material for developing a novel compound series with high efficacy against hRV-A and -B. Improved metabolic stability was achieved by substituting an ester moiety with a 1,2,4-oxadiazole group. Specifically, compound 3k exhibited a high efficacy against hRV-B14, hRV-A21, and hRV-A71, with EC50 values of 66.0, 22.0, and 3.7 nM, respectively, and a relevant hepatic stability (59.6 and 40.7% compound remaining after 30 min in rat and human liver microsomes, respectively). An in vivo study demonstrated that 3k possessed a desirable pharmacokinetic profile with low systemic clearance (0.158 L.h(-1).Kg(-1)) and modest oral bioavailability (27.8%). Hence, 3k appears to be an interesting candidate for the development of antiviral lead compounds.

  DOI：

  10.1021/acsmedchemlett.8b00134
• 作为产物：
  描述：

  4-羟基-3-甲基苯甲酸 在 ammonium hydroxide 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 21.0h， 生成 4-hydroxy-3-methylbenzamide
  参考文献：
  名称：

  3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus

  摘要：

  The human rhinovirus (hRV) is the causative agent of the common cold that often aggravates respiratory complications in patients with asthma or chronic obstructive pulmonary disease. The high rate of mutations and variety of serotypes are limiting the development of anti-hRV drugs, which emphasizes the need for the discovery of novel lead compounds. Previously, we identified antiviral compound 1 that we used here as the starting material for developing a novel compound series with high efficacy against hRV-A and -B. Improved metabolic stability was achieved by substituting an ester moiety with a 1,2,4-oxadiazole group. Specifically, compound 3k exhibited a high efficacy against hRV-B14, hRV-A21, and hRV-A71, with EC50 values of 66.0, 22.0, and 3.7 nM, respectively, and a relevant hepatic stability (59.6 and 40.7% compound remaining after 30 min in rat and human liver microsomes, respectively). An in vivo study demonstrated that 3k possessed a desirable pharmacokinetic profile with low systemic clearance (0.158 L.h(-1).Kg(-1)) and modest oral bioavailability (27.8%). Hence, 3k appears to be an interesting candidate for the development of antiviral lead compounds.

  DOI：

  10.1021/acsmedchemlett.8b00134

文献信息

• LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20170050964A1

  公开（公告）日：2017-02-23

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: P 4 —P-M-M 4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I中含有内酰胺的化合物及其衍生物：P4—P-M-M4I或其药用盐形式，其中环P（如果存在）是一个5-7成员的碳环或杂环，环M是一个5-7成员的碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa。
• Process for preparation of optically active halogeno hydroxypropyl compound and glycidyl compound
  申请人：——

  公开号：US20040024254A1

  公开（公告）日：2004-02-05

  A process for preparing regioselectively an optically active 1-halogeno-2-hydroxypropyl compound of the following formula; 1 wherein X is halogen atom and Nu is a heteroatom having a substituent, and an optically active glycidyl compound of the formula; 2 which comprises reacting an optically active epihalohydrin of the formula; 3 with a neucleophilic agent, in the presence of a metal complex of the formula; 4 wherein n is an integer of 0, 1 or 2, Y 1 , Y 2 and Y 3 are hydrogen atom, etc., and Y 2 and Y 3 may form a ring such as benzene, A is a counterion and M is a metal ion, and further subjecting the compound (4) to reaction with a base to prepare the optically active glycidyl compound (5).

  一种制备具有下列结构的手性1-卤代-2-羟基丙基化合物的区域选择性方法；其中X是卤素原子，Nu是带有取代基的杂原子，以及具有下列结构的手性环氧丙烷化合物的方法；通过在金属配合物的存在下，将具有下列结构的手性环氧卤水合物与亲核试剂反应，其中金属配合物的结构如下；其中n为0、1或2的整数，Y1、Y2和Y3为氢原子等，而Y2和Y3可以形成苯环等，A为反离子，M为金属离子，进一步将化合物（4）与碱反应以制备手性环氧丙基化合物（5）。
• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
• [EN] LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS<br/>[FR] COMPOSES CONTENANT DU LACTAME ET LEURS DERIVES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003026652A1

  公开（公告）日：2003-04-03

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了含有内酰胺化合物及其衍生物的公式I：P4-P-M-M4或其药学上可接受的盐形式，其中环P（如存在）是5-7成员的碳环或杂环，环M是5-7成员的碳环或杂环。本发明的化合物可作为胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是Xa因子的抑制剂。
• Process for producing glycidyl ether
  申请人：Furukawa Yoshiro

  公开号：US20060030721A1

  公开（公告）日：2006-02-09

  A process for producing a glycidyl ether and an optically active compound thereof with high yield and an optically high purity comprising reacting an alcohol with epihalohydrin in a base to thereby produce a glycidyl ether, the reaction performed in a two-layer system of a nonaqueous organic solvent and an aqueous solvent.

  一种生产高收率和高光学纯度的环氧丙基醚和其光学活性化合物的方法，包括在碱性条件下将醇与环氧卤代丙烷反应以产生环氧丙基醚，反应在非水有机溶剂和水溶剂的两层体系中进行。